At the Crossroads
How a new UK medicines deal can deliver for patients, the NHS and the economy
The industry’s vision for a new Voluntary Scheme for Pricing, Access and Growth (VPAG) which can deliver a sustainable approach to medicines provision while also maximising the potential of the UK life sciences industry as an engine for growth.
- Voluntary Scheme
- Statutory Scheme
Last modified: 20 September 2023
Last reviewed: 20 September 2023